EUR-Lex & EU Commission AI-Powered Semantic Search Engine
Modern Legal
  • Query in any language with multilingual search
  • Access EUR-Lex and EU Commission case law
  • See relevant paragraphs highlighted instantly
Start free trial

Similar Documents

Explore similar documents to your case.

We Found Similar Cases for You

Sign up for free to view them and see the most relevant paragraphs highlighted.

Case T-267/21: Order of the General Court of 9 November 2021 — Amort and Others v Commission (Action for annulment — Medicinal products for human use — Conditional marketing authorisation for the medicinal product for human use ‘COVID-19 Vaccine Janssen — COVID-19 vaccine (Ad26.COV2-S [recombinant])’ — No interest in bringing proceedings — Lack of direct concern — Lack of individual concern — Non-regulatory act — Inadmissibility)

ECLI:EU:UNKNOWN:62021TB0267

62021TB0267

November 9, 2021
With Google you find a lot.
With us you find everything. Try it now!

I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!

Valentina R., lawyer

17.1.2022

Official Journal of the European Union

C 24/42

(Case T-267/21) (<span class="oj-super oj-note-tag">1</span>)

(Action for annulment - Medicinal products for human use - Conditional marketing authorisation for the medicinal product for human use ‘COVID-19 Vaccine Janssen — COVID-19 vaccine (Ad26.COV2-S [recombinant])’ - No interest in bringing proceedings - Lack of direct concern - Lack of individual concern - Non-regulatory act - Inadmissibility)

(2022/C 24/55)

Language of the case: German

Parties

Applicants: Heidi Amort (Jenesien, Italy) and the 22 other applicants whose names are set out in the annex to the order (represented by: R. Holzeisen, lawyer)

Defendant: European Commission (represented by: B.-R. Killmann and A. Sipos, acting as Agents)

Re:

Application under Article 263 TFEU for annulment of Commission Implementing Decision C(2021) 1763 (final) of 11 March 2021 granting a conditional marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for ‘COVID-19 Vaccine Janssen — COVID-19 vaccine (Ad26.COV2-S [recombinant])’, a medicinal product for human use, as amended and supplemented.

Operative part of the order

1.The action is dismissed as inadmissible.

2.There is no longer any need to adjudicate on the applications for leave to intervene submitted by TF, TG, TH and TI, by TR and the other persons whose names are set out in Annex II and by VH and the other persons whose names are set out in Annex II.

3.Ms Heidi Amort and the other persons whose names are set out in Annex I shall pay the costs.

4.TF, TG, TH and TI, TR and the other persons whose names are set out in Annex II and VH and the other persons whose names are set out in Annex II shall each bear their own costs relating to the applications for leave to intervene.

(<span class="oj-super">1</span>) OJ C 263, 5.7.2021.

EurLex Case Law

AI-Powered Case Law Search

Query in any language with multilingual search
Access EUR-Lex and EU Commission case law
See relevant paragraphs highlighted instantly

Get Instant Answers to Your Legal Questions

Cancel your subscription anytime, no questions asked.Start 14-Day Free Trial

At Modern Legal, we’re building the world’s best search engine for legal professionals. Access EU and global case law with AI-powered precision, saving you time and delivering relevant insights instantly.

Contact Us

Tivolska cesta 48, 1000 Ljubljana, Slovenia